Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

There were two trials recently closed to accrual -- BRC.4 and PR.12.

NCCTG N0723 / Canadian Cancer Trials Group BRC.4 trial -- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib -- was officially closed to pre-registration as of 5:30 p.m. EST on Friday November 13, 2009 and will be closed to Final randomization as of 5:30 p.m. EST on December 4, 2009.

Unfortunately, accrual to this study was far below the expected rate and the NCCTG has decided to close it. No Canadian Cancer Trials Group patients were registered to this trial.

Canadian Cancer Trials Group PR.12 -- Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate (DART) -- was closed to further accrual as of November 12, 2009.

It was communicated to Canadian Cancer Trials Group that support (financial and drug-related) from Sanofi Aventis would not continue. The Canadian Cancer Trials Group acknowledges the rationale behind the decision and agree that further conduct of PR.12 carries a substantial risk for eventual failure.